Business
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that
About this update from Urogen Pharma Ltd.
[{"type":"text","content":" PRINCETON, N.J.--(BUSINESS WIRE)--\nUroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference to take place on March 3-5, 2025.\n\n\nTD Cowen 45th Annual Health Care Conference\n\n\n\n\nDate / Time:\n\n\n\n\n\n\nMarch 3, 2025 at 1:50 PM ET\n\n\n\n\n\n\n\n\nFormat:\n\n\n\n\n\n\nPresentation and 1x1 investor meetings\n\n\n\n\n\n\n\n\nLocation:\n\n\n\n\n\n\nBoston, MA\n\n\n\n\n\n\n\n\nWebcast Link:\n\n\n\n\n\n\nhere\n\n\n\n\n\n\n\nWebcasts from the conferences will also be available on UroGen’s Investor Relations website. A replay will be available on the site for approximately 90 days.\n\n\nAbout UroGen Pharma Ltd.\n\n\nUroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X (Twitter), @UroGenPharma.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250224504690/en/\n\nINVESTORS:\nVincent Perrone\nSenior Director, Investor Relations\[email protected]\n609-460-3588 ext. 1093\n\n\nMEDIA:\nCindy Romano\nDirector, Corporate Communications\[email protected]\n609-460-3583 ext. 1083\n\n\nSource: UroGen Pharma Ltd.","length":5385,"tagName":"div"}]